小柯机器人

生物工程角膜组织在两个临床队列中用于晚期角膜病的微创视力恢复
2022-08-14 22:22

瑞典林雪平大学Neil Lagali和Mehrdad Rafat共同合作,近期取得重要工作进展。他们研究揭示了生物工程角膜组织在两个临床队列中用于晚期角膜病的微创视力恢复。相关论文2022年8月11日在线发表于《自然—生物技术》杂志上。

研究人员介绍了一种无细胞工程角膜组织、生物工程猪结构、双交联 (BPCDX) 及其植入的微创手术方法。在印度和伊朗的一项试点可行性研究中,研究人员在20名晚期角膜受试者中植入了BPCDX,以在不去除现有组织或使用缝合线的情况下重塑原有角膜基质。

在24个月的随访期间,未观察到不良事件。研究人员记录了角膜厚度的改善(印度平均增加209±18μm,伊朗平均增加285±99μm),最大角膜曲率测量(印度平均减少13.9±7.9D,伊朗平均减少11.2±8.9D)和视力(印度的平均隐形眼镜矫正视力为20/26,伊朗的眼镜矫正视力为20/58)。14名最初失明的受试者的最终平均最佳矫正视力(眼镜或隐形眼镜)为20/36,并且恢复了对隐形眼镜佩戴的耐受性。这项工作表明,研究人员开发了一种可能比供体角膜移植同样有效、更安全、更简单、更广泛的方法来恢复视力。

据悉,角膜基质疾病造成的视力损害影响着全世界数百万人。

附:英文原文

Title: Bioengineered corneal tissue for minimally invasive vision restoration in advanced keratoconus in two clinical cohorts

Author: Rafat, Mehrdad, Jabbarvand, Mahmoud, Sharma, Namrata, Xeroudaki, Maria, Tabe, Shideh, Omrani, Raha, Thangavelu, Muthukumar, Mukwaya, Anthony, Fagerholm, Per, Lennikov, Anton, Askarizadeh, Farshad, Lagali, Neil

Issue&Volume: 2022-08-11

Abstract: Visual impairment from corneal stromal disease affects millions worldwide. We describe a cell-free engineered corneal tissue, bioengineered porcine construct, double crosslinked (BPCDX) and a minimally invasive surgical method for its implantation. In a pilot feasibility study in India and Iran (clinicaltrials.gov no. NCT04653922), we implanted BPCDX in 20 advanced keratoconus subjects to reshape the native corneal stroma without removing existing tissue or using sutures. During 24months of follow-up, no adverse event was observed. We document improvements in corneal thickness (mean increase of 209±18μm in India, 285±99μm in Iran), maximum keratometry (mean decrease of 13.9±7.9D in India and 11.2±8.9D in Iran) and visual acuity (to a mean contact-lens-corrected acuity of 20/26 in India and spectacle-corrected acuity of 20/58 in Iran). Fourteen of 14 initially blind subjects had a final mean best-corrected vision (spectacle or contact lens) of 20/36 and restored tolerance to contact lens wear. This work demonstrates restoration of vision using an approach that is potentially equally effective, safer, simpler and more broadly available than donor cornea transplantation.

DOI: 10.1038/s41587-022-01408-w

Source: https://www.nature.com/articles/s41587-022-01408-w

Nature Biotechnology:《自然—生物技术》,创刊于1996年。隶属于施普林格·自然出版集团,最新IF:68.164
官方网址:https://www.nature.com/nbt/
投稿链接:https://mts-nbt.nature.com/cgi-bin/main.plex


本期文章:《自然—生物技术》:Online/在线发表

分享到:

0